(WO201755611) 1. A method for treating or managing inflammatory bowel disease (IBD) in a patient having IBD, wherein the method comprises (a) analyzing a first level of Interleukin-5 (IL-5) in the patient; (b) administering to the patient an initial dose of a SMAD7 antisense oligonucleotide (AON); (c) analyzing a second level of IL-5 in the patient after the administering step; and wherein: i. if the second level of IL-5 is the same or higher than the first level of IL-5, then: administering to the patient a subsequent dose that is equal to or greater than the initial dose, and/or administering to the patient a subsequent dose at an equal or higher frequency than the initial dose; or ii. if the second level of IL-5 is lower than the first level of IL-5, then administering to the patient a subsequent dose that is equal to or smaller than the initial dose, and/or administering to the patient a subsequent dose at an equal or lower frequency than the initial dose. 4. A method for treating or managing IBD in a patient having IBD, wherein the method comprises (a) administering to the patient an initial dose of a SMAD7 AON; (b) analyzing the level of IL-5 in the patient after the administering step; and wherein i. if the level of IL-5 is above normal levels of IL-5, then administering to the patient a subsequent dose that is greater than or equal to the initial dose, and/or administering to the patient a subsequent dose at an equal or higher frequency than the initial dose; or ii. if the level of IL-5 is below normal levels of IL-5, then administering to the patient a subsequent dose that is equal to or smaller than the initial dose and/or administering to the patient a subsequent dose at an equal or lower frequency than the initial dose. 7. A method for treating or managing inflammatory bowel disease (IBD) in a patient having IBD, wherein the method comprises (a) analyzing the base level of IL-5 in the patient; and (b) if the base level of IL-5 is above normal levels of IL-5, then administering to the patient an initial dose of a SMAD7 AON. 64. A method for treating or managing IBD in a patient with IBD having above normal IL-5 levels following administration of a dose of a SMAD7 AON, said method comprising administering to said patient a further dose of said oligonucleotide that is greater than or equal to the prior dose. 65. A method for treating or managing IBD in a patient with IBD having below normal IL-5 levels following administration of a dose of SMAD7 AON, said method comprising administering to said patient a further dose of said oligonucleotide that is less than or equal to the prior dose. 66. A method of treating or managing IBD in a patient with IBD having above normal IL-5 levels, said method comprising administering to said patient a dose of a SMAD7 AON. 77. A method of monitoring the treatment or management of IBD in a patient with IBD, the method comprising analyzing IL-5 levels in the patient following each SMAD7 AON administration, wherein the absence of a decrease in IL-5 levels indicates that the treatment or management is not effective. 80. A method of treating or managing IBD in a patient with IBD having above normal levels of IL-5, comprising increasing the amount of a SMAD7 AON administered to the patient until IL-5 levels in the patient decrease. 82. A SMAD7 AON for use in a method for treating or managing IBD in a patient having IBD, wherein the method comprises analyzing the level of IL-5 in the patient to determine appropriate levels of SMAD7 AON administration. 84. A SMAD7 AON for use in a method for treating or managing IBD in a patient having IBD, wherein the method comprises (a) analyzing the level of IL-5 in the patient; and (b) if the level of IL-5 is above normal levels of IL-5, then administering to the patient an initial dose of the SMAD7 AON. 85. A method for treating or managing inflammatory bowel disease (IBD) in a patient having IBD, wherein the method comprises (a) analyzing a first level of IL-13 in the patient; (b) administering to the patient an initial dose of a SMAD7 AON; (c) analyzing a second level of IL- 13 in the patient after the administering step; and wherein: i. if the second level of IL-13 is the same or higher than the first level of IL-13, then: administering to the patient a subsequent dose that is equal to or greater than the initial dose, and/or administering to the patient a subsequent dose at an equal or higher frequency than the initial dose; or ii. if the second level of IL-13 is lower than the first level of IL-13, then administering to the patient a subsequent dose that is equal to or smaller than the initial dose, and/or administering to the patient a subsequent dose at an equal or lower frequency than the initial dose. 88. A method for treating or managing IBD in a patient having IBD, wherein the method comprises (a) administering to the patient an initial dose of a SMAD7 AON; (b) analyzing the level of IL-13 in the patient after the administering step; and wherein i. if the level of IL-13 is above normal levels of IL-13, then administering to the patient a subsequent dose that is greater than or equal to the initial dose, and/or administering to the patient a subsequent dose at an equal or higher frequency than the initial dose; or ii. if the level of IL-13 is below normal levels of IL-13, then administering to the patient a subsequent dose that is equal to or smaller than the initial dose and/or administering to the patient a subsequent dose at an equal or lower frequency than the initial dose. 91. A method for treating or managing inflammatory bowel disease (IBD) in a patient having IBD, wherein the method comprises (a) analyzing the base level of IL-13 in the patient; and (b) if the base level of IL-13 is above normal levels of IL-13, then administering to the patient an initial dose of a SMAD7 AON. 148. A method for treating or managing IBD in a patient with IBD having above normal IL-13 levels following administration of a dose of a SMAD7 AON, said method comprising administering to said patient a further dose of said oligonucleotide that is greater than or equal to the prior dose. 149. A method for treating or managing IBD in a patient with IBD having below normal IL-13 levels following administration of a dose of SMAD7 AON, said method comprising administering to said patient a further dose of said oligonucleotide that is less than or equal to the prior dose. 150. A method of treating or managing IBD in a patient with IBD having above normal IL-13 levels, said method comprising administering to said patient a dose of a SMAD7 AON. 161. A method of monitoring the treatment or management of IBD in a patient with IBD, the method comprising analyzing IL-13 levels in the patient following each SMAD7 AON administration, wherein the absence of a decrease in IL-13 levels indicates that the treatment or management is not effective. 164. A method of treating or managing IBD in a patient with IBD having above normal levels of IL-13, comprising increasing the amount of a SMAD7 AON administered to the patient until IL-13 levels in the patient decrease. 166. A SMAD7 AON for use in a method for treating or managing IBD in a patient having IBD, wherein the method comprises analyzing the level of IL-13 in the patient to determine appropriate levels of SMAD7 AON administration. 168. A SMAD7 AON for use in a method for treating or managing IBD in a patient having IBD, wherein the method comprises (a) analyzing the level of IL-13 in the patient; and (b) if the level of IL-13 is above normal levels of IL-13, then administering to the patient an initial dose of the SMAD7 AON. 169. A method for treating or managing inflammatory bowel disease (IBD) in a patient having IBD, wherein the method comprises (a) analyzing a first level of IL-25 in the patient; (b) administering to the patient an initial dose of a SMAD7 AON; (c) analyzing a second level of IL- 25 in the patient after the administering step; and wherein: i. if the second level of IL-25 is the same or higher than the first level of IL-25, then: administering to the patient a subsequent dose that is equal to or greater than the initial dose, and/or administering to the patient a subsequent dose at an equal or higher frequency than the initial dose; or ii. if the second level of IL-25 is lower than the first level of IL-25, then administering to the patient a subsequent dose that is equal to or smaller than the initial dose, and/or administering to the patient a subsequent dose at an equal or lower frequency than the initial dose. 172. A method for treating or managing IBD in a patient having IBD, wherein the method comprises (a) administering to the patient an initial dose of a SMAD7 AON; (b) analyzing the level of IL-25 in the patient after the administering step; and wherein i. if the level of IL-25 is above normal levels of IL-25, then administering to the patient a subsequent dose that is greater than or equal to the initial dose, and/or administering to the patient a subsequent dose at an equal or higher frequency than the initial dose; or ii. if the level of IL-25 is below normal levels of IL-25, then administering to the patient a subsequent dose that is equal to or smaller than the initial dose and/or administering to the patient a subsequent dose at an equal or lower frequency than the initial dose. 175. A method for treating or managing inflammatory bowel disease (IBD) in a patient having IBD, wherein the method comprises (a) analyzing the base level of IL-25 in the patient; and (b) if the base level of IL-25 is above normal levels of IL-25, then administering to the patient an initial dose of a SMAD7 AON. 232. A method for treating or managing IBD in a patient with IBD having above normal IL-25 levels following administration of a dose of a SMAD7 AON, said method comprising administering to said patient a further dose of said oligonucleotide that is greater than or equal to the prior dose. 233. A method for treating or managing IBD in a patient with IBD having below normal IL-25 levels following administration of a dose of SMAD7 AON, said method comprising administering to said patient a further dose of said oligonucleotide that is less than or equal to the prior dose. 234. A method of treating or managing IBD in a patient with IBD having above normal IL-25 levels, said method comprising administering to said patient a dose of a SMAD7 AON. 245. A method of monitoring the treatment or management of IBD in a patient with IBD, the method comprising analyzing IL-25 levels in the patient following each SMAD7 AON administration, wherein the absence of a decrease in IL-25 levels indicates that the treatment or management is not effective. 248. A method of treating or managing IBD in a patient with IBD having above normal levels of IL-25, comprising increasing the amount of a SMAD7 AON administered to the patient until IL-25 levels in the patient decrease. 250. A SMAD7 AON for use in a method for treating or managing IBD in a patient having IBD, wherein the method comprises analyzing the level of IL-25 in the patient to determine appropriate levels of SMAD7 AON administration. 252. A SMAD7 AON for use in a method for treating or managing IBD in a patient having IBD, wherein the method comprises (a) analyzing the level of IL-25 in the patient; and (b) if the level of IL-25 is above normal levels of IL-25, then administering to the patient an initial dose of the SMAD7 AON. 253. A method for treating or managing inflammatory bowel disease (IBD) in a patient having IBD, wherein the method comprises (a) analyzing a first level of REG3a in the patient; (b) administering to the patient an initial dose of a SMAD7 AON; (c) analyzing a second level of REG3a in the patient after the administering step; and wherein: i. if the second level of REG3a is the same or higher than the first level of REG3a, then: administering to the patient a subsequent dose that is equal to or greater than the initial dose, and/or administering to the patient a subsequent dose at an equal or higher frequency than the initial dose; or ii. if the second level of REG3a is lower than the first level of REG3a, then administering to the patient a subsequent dose that is equal to or smaller than the initial dose, and/or administering to the patient a subsequent dose at an equal or lower frequency than the initial dose. 256. A method for treating or managing IBD in a patient having IBD, wherein the method comprises (a) administering to the patient an initial dose of a SMAD7 AON; (b) analyzing the level of REG3a in the patient after the administering step; and wherein i. if the level of REG3a is above normal levels of REG3a, then administering to the patient a subsequent dose that is greater than or equal to the initial dose, and/or administering to the patient a subsequent dose at an equal or higher frequency than the initial dose; or ii. if the level of REG3a is below normal levels of REG3a, then administering to the patient a subsequent dose that is equal to or smaller than the initial dose and/or administering to the patient a subsequent dose at an equal or lower frequency than the initial dose. 259. A method for treating or managing inflammatory bowel disease (IBD) in a patient having IBD, wherein the method comprises (a) analyzing the base level of REG3a in the patient; and (b) if the base level of REG3a is above normal levels of REG3a, then administering to the patient an initial dose of a SMAD7 AON. 316. A method for treating or managing IBD in a patient with IBD having above normal REG3a levels following administration of a dose of a SMAD7 AON, said method comprising administering to said patient a further dose of said oligonucleotide that is greater than or equal to the prior dose. 317. A method for treating or managing IBD in a patient with IBD having below normal REG3a levels following administration of a dose of SMAD7 AON, said method comprising administering to said patient a further dose of said oligonucleotide that is less than or equal to the prior dose. 318. A method of treating or managing IBD in a patient with IBD having above normal REG3a levels, said method comprising administering to said patient a dose of a SMAD7 AON. 329. A method of monitoring the treatment or management of IBD in a patient with IBD, the method comprising analyzing REG3a levels in the patient following each SMAD7 AON administration, wherein the absence of a decrease in REG3a levels indicates that the treatment or management is not effective. 332. A method of treating or managing IBD in a patient with IBD having above normal levels of REG3a, comprising increasing the amount of a SMAD7 AON administered to the patient until REG3a levels in the patient decrease. 334. A SMAD7 AON for use in a method for treating or managing IBD in a patient having IBD, wherein the method comprises analyzing the level of REG3a in the patient to determine appropriate levels of SMAD7 AON administration. 336. A SMAD7 AON for use in a method for treating or managing IBD in a patient having IBD, wherein the method comprises (a) analyzing the level of REG3a in the patient; and (b) if the level of REG3a is above normal levels of REG3a, then administering to the patient an initial dose of the SMAD7 AON.
最新评论
暂无评论。